Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
Seagen Inc.
KaliVir Immunotherapeutics
iOnctura
Sotio Biotech Inc.
Novartis
Kezar Life Sciences, Inc.
NeoTX Therapeutics Ltd.
HiFiBiO Therapeutics
Incyte Corporation
Actym Therapeutics, Inc.
Incyte Corporation
Turnstone Biologics, Corp.
Molecular Templates, Inc.
NGM Biopharmaceuticals, Inc
University of California, San Diego
Pfizer
NGM Biopharmaceuticals, Inc
Xencor, Inc.
AbbVie
AbbVie
Infinity Pharmaceuticals, Inc.
MacroGenics
Incyte Corporation
Incyte Corporation
University of Chicago
Mannkind Corporation